Table 3. Adenovirus vector vaccine effectiveness in the chronically ill aged 16–69 years adjusted for age group, sex, presence of medical conditions and residence in Helsinki-Uusimaa.
| Laboratory-confirmed SARS-CoV-2 infection | Covid-19 hospitalisation | |||||
|---|---|---|---|---|---|---|
| Cases, n | Cumulative riska | Vaccine effectivenes, % | Cases, n | Cumulative riska | Vaccine effectivenessb, % | |
| Not vaccinated | 5280 | 859 | Reference | 528 | 90 | Reference |
| First dose | ||||||
| 21–27 DSV | 51 | 238 | 24 (-1 to 42) | 4 | 42 | 67 (10–88) |
| 28–34 DSV | 29 | 129 | 48 (25–64) | 1 | 3 | 91 (33–99) |
| 35–41 DSV | 29 | 184 | 37 (8–56) | 6 | 37 | 36 (-45 to 72) |
| 42+ DSV | 78 | 106 | 50 (37–61) | 15 | 21 | 58 (26–76) |
| Second dose | ||||||
| 7+ DSV | 0 | 0 | Not estimated | 0 | 0 | Not estimated |
a Cumulative risk at the end of the study multiplied by 10000;
b Point estimate and 95% confidence interval; DSV, days since vaccination.